On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
REGULATORY
MHLW Unveils List of “Stable Supply Medicines”
The Ministry of Health, Labor and Welfare (MHLW) on February 26 unveiled a list of what is called “stable supply medicines” deemed to be essential in clinical practices, with 21 products sorted into a group with the highest priority among…
To read the full story
Related Article
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
- Japan to Expand List of “Stable Supply Medicines” to 759 APIs, Adding Vaccines and Blood Products
August 28, 2025
- MHLW Working Group Sets Policy for Revising List of “Stable Supply Medicines”
August 18, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- MHLW to Update List of “Stable Supply Medicines” Eyeing Expansion
October 25, 2024
- Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
- MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
March 30, 2021
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
REGULATORY
- Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
November 12, 2026
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- Japan to List Eylea Biosimilars from SamChunDang, Celltrion on Nov. 13
November 12, 2026
- PMDA Sees Little Need for Separate Dosage Form Category for Mini-Tablets
November 11, 2026
- Japan Eyes Nationwide Probe into Wartime Drug Trials on Leprosy Patients
November 11, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…